Video Replay: AI Discussion with CEO Dr. Serge Saxonov from 10x Genomics (TXG)

Research evidence excerpt

Video Replay: AI Discussion with CEO Dr. Serge Saxonov from 10x Genomics (TXG)

USA | Life Science Tools & Diagnostics

10x Genomics EquityJulyResearch1, 2026

FLASH NOTEVideo Replay: AI Discussion with CEO Dr. Serge

RATING BUYSaxonov from 10x Genomics (TXG)

PRICE $39.05^

We hosted a call with CEO Dr. Serge Saxonov from 10x Genomics to discuss all

things AI in the business. Please see here for the video replay. PRICE TARGET | % TO PT $40.00 | +2%

52W HIGH-LOW $40.08 - $11.16

AI a tailwind, not a threat. CEO Dr. Serge Saxonov was unequivocal that AI represents a significant FLOAT (%) | ADV MM (USD) 88.2% | 135.52

tailwind for 10x Genomics, arguing that the bearish view incorrectly assumes biology is sufficiently MARKET CAP $5.0B

understood to be modeled without generating large new datasets. This conviction is driving TICKER TXG

increased investments across AI initiatives, including the STELA/Bioptimus partnership, where ^Prior trading day's closing price unless otherwise

10x is helping generate massive spatial datasets at scale. Importantly, these projects primarily noted.

drive instrument placements and consumables pull-through today, while longer-term opportunities

around data monetization remain exploratory. For now, management emphasized that the core

business remains selling the “picks and shovels” required to build AI-ready biological datasets.

Single cell, software and pharma. Management highlighted BioTuring as a complementary

partnership that broadens access to sophisticated analysis through user interfaces. At the same

time, 10x Cloud is being developed as an enablement layer to store, manage, share, and analyze

increasingly large datasets, particularly as customers transition into higher-throughput Atera.